Key result
Elevated cardiac troponin-I occurred in 36% of patients after PTCA (vs 9% for CK-MB, p=0.002), but did not predict adverse events, which occurred in 18% of patients overall over 1375 days.
Why the study?
Does an increase in cardiac troponin-I shortly after successful PTCA predict worse long-term prognosis?
Cohort (n=44)
Does an increase in cardiac troponin-I shortly after successful PTCA predict worse long-term prognosis?
While cTn-I is more sensitive than CK-MB for detecting minor myocardial damage after PTCA, its short-term elevation does not appear to predict worse long-term clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Post-PTCA troponin elevation should not yet change follow-up; leaves open its added prognostic value versus CK-MB in larger cohorts.
Attali et al. (1998) conducted a cohort in Post-percutaneous transluminal coronary angioplasty (PTCA) (n=44). Elevated cardiac troponin-I vs. Normal cardiac troponin-I was evaluated on Adverse events (free-event survival). Elevated cardiac troponin-I occurred in 36% of patients after PTCA (vs 9% for CK-MB, p=0.002), but did not predict adverse events, which occurred in 18% of patients overall over 1375 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: